27,468 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Monument Capital Management

Monument Capital Management acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the third quarter, Holdings Channel reports. The fund acquired 27,468 shares of the biopharmaceutical company’s stock, valued at approximately $2,015,000.

Other hedge funds also recently added to or reduced their stakes in the company. DLD Asset Management LP acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $650,250,000. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 127.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after buying an additional 1,425,674 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in Halozyme Therapeutics during the second quarter valued at approximately $51,295,000. Los Angeles Capital Management LLC raised its stake in Halozyme Therapeutics by 951.8% during the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock valued at $50,650,000 after buying an additional 881,094 shares in the last quarter. Finally, Norges Bank bought a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $45,027,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of research analyst reports. Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. JPMorgan Chase & Co. raised their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th. Benchmark boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Halozyme Therapeutics in a report on Monday, December 15th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $75.10.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $68.16 on Tuesday. The firm has a fifty day moving average of $67.19 and a 200-day moving average of $65.16. The company has a market cap of $8.02 billion, a price-to-earnings ratio of 14.35, a price-to-earnings-growth ratio of 0.36 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. Halozyme Therapeutics, Inc. has a 1 year low of $46.26 and a 1 year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.27 EPS. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction that occurred on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total transaction of $277,904.97. Following the sale, the chief operating officer owned 12,737 shares of the company’s stock, valued at approximately $830,325.03. The trade was a 25.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bernadette Connaughton sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $71.60, for a total value of $59,356.40. Following the transaction, the director owned 42,123 shares of the company’s stock, valued at approximately $3,016,006.80. This represents a 1.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 85,661 shares of company stock worth $6,036,837. 2.90% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.